We enumerated the positive or negative modulatory effects of PTPN2 in a variety of cancers, including intestinal cancers, breast cancer, glioma, hepatocellular carcinoma, skin cancer, lung cancer, ovarian cancer, laryngeal cancer, thyroid cancer, and B-cell lymphoma. Here, PTPN2 is linked to central nervous system cancer.